Exelixis | EXEL - Trade Creditors


Exelixis reported $24.15M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
Agios Pharmaceuticals USD 13.75M 4.61M Mar/2026
Akebia Therapeutics USD 8.39M 12.8M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
AstraZeneca USD 22.51B 2.78B Mar/2026
Bayer EUR 6.59B 496M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Cytokinetics USD 24.71M 80.91M Mar/2026
Eisai JPY 75.89B 9.6B Mar/2026
Eli Lilly USD 5.03B 350M Mar/2026
Esperion Therapeutics USD 68.41M 3.34M Mar/2026
Exelixis USD 24.15M 5.47M Mar/2026
Genmab DKK 6M 2M Sep/2025
Glaxosmithkline GBP 20.72B 346.14M Dec/2025
Incyte USD 228.62M 1.41B Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
MacroGenics USD 4.29M 500K Mar/2026
Merck USD 3.86B 541M Mar/2026
Moderna USD 161M 156M Mar/2026
Nektar Therapeutics USD 10.77M 4.79M Dec/2025
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Sanofi EUR 22.93B 2.89B Dec/2025
Takeda JPY 491.34B 23.75B Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Xencor USD 7.92M 2.91M Mar/2026